Loading…
Linezolid therapy of Staphylococcus aureus experimental osteomyelitis
The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 microg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no anti...
Saved in:
| Published in: | Antimicrobial agents and chemotherapy 2000-12, Vol.44 (12), p.3438-3440 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393 |
| container_end_page | 3440 |
| container_issue | 12 |
| container_start_page | 3438 |
| container_title | Antimicrobial agents and chemotherapy |
| container_volume | 44 |
| creator | PATEL, Robin PIPER, Kerryl E ROUSE, Mark S STECKELBERG, James M |
| description | The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 microg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 microg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 microg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment. |
| doi_str_mv | 10.1128/AAC.44.12.3438-3440.2000 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_90219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72421603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393</originalsourceid><addsrcrecordid>eNqFkc1q3DAURkVoaSZJX6EYCt3Z0Z9lGboZhjQJDGSRZi2uZSmjorFcyS6ZPH1lMqTNKqsr0Pkun3QQKgiuCKHycr3eVJxXhFaMM1kyznFFMcYnaEVwK0tRt-IDWmEsRMkl5qfoLKVfGcgX-BM6JQRLJmq-QldbN5jn4F1fTDsTYTwUwRb3E4y7gw86aD2nAuZo8jBPo4lub4YJfBHSZML-YLybXLpAHy34ZD4f5zl6-HH1c3NTbu-ubzfrbal5w6aSd72lWlvRMNZ1wGvLsLTS9DXhYOuaUNq1TSsoZULQDmowfT4a0hFoCGvZOfr-snecu73pda4Swasxt4J4UAGcenszuJ16DH9UiylZ4t-O8Rh-zyZNau-SNt7DYMKcVEM5JQKzd0HS5O_jcgHlC6hjSCka-9qFYLWoUlmV4lwRqhZValGlFlU5-uX_t_wLHt1k4OsRgKTB2wiDdumVk3lJbvAXm_aebw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17836483</pqid></control><display><type>article</type><title>Linezolid therapy of Staphylococcus aureus experimental osteomyelitis</title><source>Open Access: PubMed Central</source><source>ASM_美国微生物学会期刊</source><creator>PATEL, Robin ; PIPER, Kerryl E ; ROUSE, Mark S ; STECKELBERG, James M</creator><creatorcontrib>PATEL, Robin ; PIPER, Kerryl E ; ROUSE, Mark S ; STECKELBERG, James M</creatorcontrib><description>The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 microg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 microg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 microg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.44.12.3438-3440.2000</identifier><identifier>PMID: 11083654</identifier><identifier>CODEN: AACHAX</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Acetamides - blood ; Acetamides - therapeutic use ; Animals ; Anti-Bacterial Agents - blood ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; cefazolin ; Colony Count, Microbial ; Disease Models, Animal ; Experimental Therapeutics ; Humans ; Linezolid ; Male ; Medical sciences ; Osteomyelitis - blood ; Osteomyelitis - drug therapy ; Oxazolidinones - blood ; Oxazolidinones - therapeutic use ; Pharmacology. Drug treatments ; Rats ; Rats, Wistar ; Staphylococcal Infections - blood ; Staphylococcal Infections - drug therapy ; Staphylococcus aureus ; Staphylococcus aureus - drug effects</subject><ispartof>Antimicrobial agents and chemotherapy, 2000-12, Vol.44 (12), p.3438-3440</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright © 2000, American Society for Microbiology 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393</citedby><cites>FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC90219/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC90219/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3188,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=800083$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11083654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PATEL, Robin</creatorcontrib><creatorcontrib>PIPER, Kerryl E</creatorcontrib><creatorcontrib>ROUSE, Mark S</creatorcontrib><creatorcontrib>STECKELBERG, James M</creatorcontrib><title>Linezolid therapy of Staphylococcus aureus experimental osteomyelitis</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><description>The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 microg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 microg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 microg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.</description><subject>Acetamides - blood</subject><subject>Acetamides - therapeutic use</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - blood</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>cefazolin</subject><subject>Colony Count, Microbial</subject><subject>Disease Models, Animal</subject><subject>Experimental Therapeutics</subject><subject>Humans</subject><subject>Linezolid</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Osteomyelitis - blood</subject><subject>Osteomyelitis - drug therapy</subject><subject>Oxazolidinones - blood</subject><subject>Oxazolidinones - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Staphylococcal Infections - blood</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkc1q3DAURkVoaSZJX6EYCt3Z0Z9lGboZhjQJDGSRZi2uZSmjorFcyS6ZPH1lMqTNKqsr0Pkun3QQKgiuCKHycr3eVJxXhFaMM1kyznFFMcYnaEVwK0tRt-IDWmEsRMkl5qfoLKVfGcgX-BM6JQRLJmq-QldbN5jn4F1fTDsTYTwUwRb3E4y7gw86aD2nAuZo8jBPo4lub4YJfBHSZML-YLybXLpAHy34ZD4f5zl6-HH1c3NTbu-ubzfrbal5w6aSd72lWlvRMNZ1wGvLsLTS9DXhYOuaUNq1TSsoZULQDmowfT4a0hFoCGvZOfr-snecu73pda4Swasxt4J4UAGcenszuJ16DH9UiylZ4t-O8Rh-zyZNau-SNt7DYMKcVEM5JQKzd0HS5O_jcgHlC6hjSCka-9qFYLWoUlmV4lwRqhZValGlFlU5-uX_t_wLHt1k4OsRgKTB2wiDdumVk3lJbvAXm_aebw</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>PATEL, Robin</creator><creator>PIPER, Kerryl E</creator><creator>ROUSE, Mark S</creator><creator>STECKELBERG, James M</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>C1K</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20001201</creationdate><title>Linezolid therapy of Staphylococcus aureus experimental osteomyelitis</title><author>PATEL, Robin ; PIPER, Kerryl E ; ROUSE, Mark S ; STECKELBERG, James M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acetamides - blood</topic><topic>Acetamides - therapeutic use</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - blood</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>cefazolin</topic><topic>Colony Count, Microbial</topic><topic>Disease Models, Animal</topic><topic>Experimental Therapeutics</topic><topic>Humans</topic><topic>Linezolid</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Osteomyelitis - blood</topic><topic>Osteomyelitis - drug therapy</topic><topic>Oxazolidinones - blood</topic><topic>Oxazolidinones - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Staphylococcal Infections - blood</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PATEL, Robin</creatorcontrib><creatorcontrib>PIPER, Kerryl E</creatorcontrib><creatorcontrib>ROUSE, Mark S</creatorcontrib><creatorcontrib>STECKELBERG, James M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PATEL, Robin</au><au>PIPER, Kerryl E</au><au>ROUSE, Mark S</au><au>STECKELBERG, James M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Linezolid therapy of Staphylococcus aureus experimental osteomyelitis</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>44</volume><issue>12</issue><spage>3438</spage><epage>3440</epage><pages>3438-3440</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><coden>AACHAX</coden><abstract>The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 microg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 microg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 microg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>11083654</pmid><doi>10.1128/AAC.44.12.3438-3440.2000</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial agents and chemotherapy, 2000-12, Vol.44 (12), p.3438-3440 |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_90219 |
| source | Open Access: PubMed Central; ASM_美国微生物学会期刊 |
| subjects | Acetamides - blood Acetamides - therapeutic use Animals Anti-Bacterial Agents - blood Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences cefazolin Colony Count, Microbial Disease Models, Animal Experimental Therapeutics Humans Linezolid Male Medical sciences Osteomyelitis - blood Osteomyelitis - drug therapy Oxazolidinones - blood Oxazolidinones - therapeutic use Pharmacology. Drug treatments Rats Rats, Wistar Staphylococcal Infections - blood Staphylococcal Infections - drug therapy Staphylococcus aureus Staphylococcus aureus - drug effects |
| title | Linezolid therapy of Staphylococcus aureus experimental osteomyelitis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A07%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Linezolid%20therapy%20of%20Staphylococcus%20aureus%20experimental%20osteomyelitis&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=PATEL,%20Robin&rft.date=2000-12-01&rft.volume=44&rft.issue=12&rft.spage=3438&rft.epage=3440&rft.pages=3438-3440&rft.issn=0066-4804&rft.eissn=1098-6596&rft.coden=AACHAX&rft_id=info:doi/10.1128/AAC.44.12.3438-3440.2000&rft_dat=%3Cproquest_pubme%3E72421603%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c473t-4bdf2ccf6733bba45f308f8ed514af55122b9796223662ba5aed236e1b1a71393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17836483&rft_id=info:pmid/11083654&rfr_iscdi=true |